MARLBOROUGH, Mass.,
March 16, 2015 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering and developing
innovative therapeutics addressing high-unmet medical needs
primarily in the area of dermatology and ophthalmology today
announced that it will report financial results for the fourth
quarter and year ended December 31,
2014 on Monday, March 30, 2015
after the close of the U.S. financial markets.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
A live audio webcast will begin at 4:30
p.m. EDT. The webcast link is available under the
"Investors" section of the Company's website,
www.rxipharma.com. The event may also be accessed by dialing
toll-free in the United States and
Canada: +1 888-669-0684.
International participants may access the event by dialing: +1
862-225-5361. An archive of the webcast will be available on
the company's website approximately two hours after the
presentation.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics addressing high-unmet medical needs
primarily in the area of dermatology and ophthalmology. Our
discovery and clinical development programs are based on siRNA
technology as well as immunotherapy agents. These compounds
include, but are not limited to, our proprietary, self-delivering
RNAi (sd-rxRNA®) compounds for the treatment of dermal
and retinal scarring. It also includes an immunomodulator,
Samcyprone™, a proprietary gel formulation of
diphenylcyclopropenone (DPCP), for the treatment of such disorders
as alopecia areata, warts, and cutaneous metastases of
melanoma.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum. We are committed to being a
partner of choice for academia, small companies, and large
multinationals. We welcome ideas and proposals for strategic
alliances, including in- and out-licensing opportunities, to
advance and further develop strategic areas of interest.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements
about future expectations and planned and future development of our
product candidates, technologies and partnerships.
Forward-looking statements about expectations and development
plans of RXi's product candidates and partnerships involve
significant risks and uncertainties, including the following: risks
that we may not be able to successfully develop and commercialize
our product candidates; risks that product development and clinical
studies may be delayed, not proceed as planned and/or be subject to
significant cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-webcast-fourth-quarter-and-year-end-2014-financial-results-on-monday-march-30-2015-300050572.html
SOURCE RXi Pharmaceuticals Corporation